Mavrilimumab for severe COVID-19
Lancet Rheumatol
.
2020 Nov;2(11):e661-e662.
doi: 10.1016/S2665-9913(20)30306-4.
Epub 2020 Sep 5.
Authors
Adil Rashid Khan
1
,
Manish Soneja
1
,
Praveen Kumar Tirlangi
2
,
Naveet Wig
1
Affiliations
1
Department of Medicine, All India Institute of Medical Sciences, New Delhi, 110029 India.
2
Department of Infectious Diseases, All India Institute of Medical Sciences, New Delhi, 110029 India.
PMID:
33521661
PMCID:
PMC7833724
DOI:
10.1016/S2665-9913(20)30306-4
No abstract available